Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-15.07	-17.46	-18.8	-48.98	-6.86	-2.41
Depreciation & Amortization	0.38	0.41	0.44	0.68	0.12	0
Share-Based Compensation	1.97	2.15	2.62	12.6	1.98	0.62
Other Operating Activities	1.17	0.64	-1.73	24.24	0.88	1.14
Operating Cash Flow	-11.56	-14.09	-17.15	-11.46	-3.89	-0.65
Capital Expenditures	0.02	0.01	-0.58	-0.19	0	0
Acquisitions	0	0	0	2.38	0	0
Other Investing Activities	-	-	-	-	-0.04	-
Investing Cash Flow	0.02	0.01	-0.58	2.19	-0.04	0
Share Issuance / Repurchase	4.13	0	17.22	24.9	3.86	0
Debt Issued / Paid	0	0	0	0	1.67	0.56
Other Financing Activities	1.19	-1.34	0.96	-	-	-
Financing Cash Flow	5.32	-1.34	18.18	24.9	5.53	0.56
Exchange Rate Effect	0.02	-0.01	-0.08	0.14	-0.06	0.02
Net Cash Flow	-6.21	-15.44	0.37	15.78	1.53	-0.07
Free Cash Flow	-11.54	-14.08	-17.73	-11.65	-3.89	-0.65
Free Cash Flow Per Share	-2.88	-6.52	-12.26	-24.66	-33.79	-6.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).